The drug, Kymriah, is the first CAR-T therapy to come before the FDA and was approved for the treatment of patients up to 25 years old with relapsed acute lymphoblastic leukemia.
A clinical trial of the leukemia drug deemed a “breakthrough” by physicians revealed 83 percent of patients treated with CAR-T cell therapy have gone into remission.
While the price tag of $475,000 per treatment seems staggering, it is much less than the $649,000 per treatment price analysts expected.
“We’re entering a new frontier in medical innovation with the ability to reprogram a patient’s own cells to attack a deadly cancer,” said FDA Commissioner Scott Gottlieb, MD.
The FDA’s approval came weeks earlier than expected.
More articles on supply chain:
US Bioservices to pay $13.4M to resolve kickback suit
Samsung widens stake in prescription drug market through partnership with Japanese pharmaceutical company
Patients brace for price of ‘breakthrough’ leukemia drug CTL019
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.
